#AS­CO17 high­lights: Roche ush­ers ear­ly-stage bis­pe­cif­ic in­to view; Agios, Cel­gene un­veil more AG-221 da­ta; Plen­ty more com­ing at AS­CO

Roche has an ear­ly-stage T cell bis­pe­cif­ic — which binds si­mul­ta­ne­ous­ly to T cells and tu­mor cells — called CEA-TCB (RO6958688; RG7802) that it is bull­ish about. It re­leased a very ear­ly look at Phase I da­ta for AS­CO, look­ing at monother­a­py as well as a com­bo with its check­point Tecen­triq. The da­ta demon­strate: “In the monother­a­py, out of 31 pa­tients with mCRC treat­ed with CEA-TCB dos­es of 60mg or above, 14 pa­tients (45%) showed ei­ther par­tial re­sponse (n=2, 6%) or sta­ble dis­ease (n=12, 39%). For the com­bi­na­tion, of 25 pa­tients treat­ed with dos­es of 5–160mg of CEA-TCB, 11 pa­tients with MSS mCRC were treat­ed at dos­es shown to in­duce tu­mour le­sion in­flam­ma­tion (80 and 160 mg). Nine of these pa­tients (82%) showed ei­ther a par­tial re­sponse (n=2, 18%) or sta­ble dis­ease (n=7, 64%) in this dif­fi­cult-to-treat pop­u­la­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.